A Non-randomized, Open Label, Multi-center Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Patients With Metastatic and/or Unresectable GIST Resistant or Refractory to Prior Systemic Treatments Including Imatinib and Sunitinib.

Trial Profile

A Non-randomized, Open Label, Multi-center Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Patients With Metastatic and/or Unresectable GIST Resistant or Refractory to Prior Systemic Treatments Including Imatinib and Sunitinib.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2016

At a glance

  • Drugs Ganetespib (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Biomarker; Therapeutic Use
  • Sponsors Synta Pharmaceuticals
  • Most Recent Events

    • 03 Mar 2014 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov record.
    • 20 Mar 2012 Planned End Date changed from 1 Nov 2011 to 1 Sep 2012 as reported by ClinicalTrials.gov.
    • 20 Mar 2012 Status changed from recruiting to active, no longer recruiting as reported byClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top